NMN (Nicotinamide Mononucleotide) is a direct precursor to NAD+ (Nicotinamide Adenine Dinucleotide), a critical coenzyme required for cellular energy production and the activation of longevity pathways, particularly sirtuins and PARPs. NAD+ levels decline significantly with age, leading to mitochondrial dysfunction and reduced cellular repair capacity. Supplementation with NMN has been shown to effectively raise systemic NAD+ levels, improving vascular health, endurance, and metabolic markers in aging animal models, with early human trials showing favorable safety and modest metabolic benefits.
Verdict
A promising, albeit expensive, supplement for rescuing metabolic decline associated with aging.
HEALTHSPAN IMPACT
High Value
RISK LEVEL
Low
EVIDENCE GRADE
C
MONTHLY COST
$30 - $120
Protocol
- Oral or sublingual dosing of 250mg to 1000mg daily, typically taken in the morning.
Flags
- Recent regulatory disputes with the FDA over its status as a dietary supplement vs. investigational drug.
- High prevalence of counterfeit or degraded products on the supplement market; sourcing is critical.
- Theoretical concerns about fueling existing cancers, as tumors also rely on NAD+ for rapid growth.
- May require concurrent supplementation with methyl donors (like TMG) to prevent methyl depletion.